Combining biomarkers to predict patient outcome. A: ZAP-70 and IGHV Mutation Status.28 Figure shows time from diagnosis to first treatment based on the combination of ZAP-70 and IGHV mutation status. Reprinted with permission of the American Society of Hematology. This research was originally published in Blood by Rassenti et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008;112:1923–1930 © the American Society of Hematology. B: FISH and IGHV Mutation Status.33 Figure shows survival from diagnosis among Binet stage A patients based on combination of FISH and IGHV mutation status. Patients with del(17p13) or del(11q22) are classified by FISH category regardless of the results of IGHV testing. Patients without del(17p13) or del(11q22) are stratified as unmutated (VH homology ≥ 98%) or mutated (VH homology<98%) based on IGHV testing. Reprinted with permission of the American Society of Hematology. This research was originally published in Blood by Krober et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100:1410–1416 © the American Society of Hematology.
